Attention AACR Annual Meeting 2018 Registrants – Activate Your Access

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

  • Sort by:
  • Browse by:
<< first | < prev page: of 3 records per page: next > | last >>
pages: 1 2 3 presentations: 1 to 25 of 71
Welcome from AACR Chief Executive Officer
Margaret Foti
American Association for Cancer Research, Philadelphia, PA, United States
from 2018 Advances in Malignant Lymphoma conference on June 22, 2018 6:00 PM-8:00 PM
Welcome from Scientific Committee Chair
Ari M Melnick
Weill Cornell Medical College, New York, NY, United States
from 2018 Advances in Malignant Lymphoma conference on June 22, 2018 6:00 PM-8:00 PM
Keynote Address: Immunogenicity Predicts Prevention
Michael A Caligiuri
City of Hope National Medical Center, Duarte, CA, United States
from 2018 Advances in Malignant Lymphoma conference on June 22, 2018 6:00 PM-8:00 PM
Keynote Address: CAR T for lymphoma and beyond
Carl H June
Univ. of Pennsylvania, Philadelphia, PA, United States
from 2018 Advances in Malignant Lymphoma conference on June 22, 2018 6:00 PM-8:00 PM
Panel Discussion
Ari M Melnick
Weill Cornell Medical College, New York, NY, United States
Michael A Caligiuri
City of Hope National Medical Center, Duarte, CA, United States
Carl H June
Univ. of Pennsylvania, Philadelphia, PA, United States
from 2018 Advances in Malignant Lymphoma conference on June 22, 2018 6:00 PM-8:00 PM
Panelist
Cheryl A London
Tufts Medical Center, Boston, MA, United States
Panelist
Laura Marconato
Centro Oncologico Veterinario, Sasso Marconi, Italy
from 2018 Advances in Malignant Lymphoma conference on June 23, 2018 7:15 AM-8:00 AM
Panelist
Lisa G. Roth
Weill Cornell Medical College of Cornell University, New York, NY, United States
Panelist
Kieron Dunleavy
George Washington Univ., Washington, DC, United States
from 2018 Advances in Malignant Lymphoma conference on June 23, 2018 7:15 AM-8:00 AM
Precision medicine based on the genetic taxonomy of DLBCL
Louis M Staudt
National Cancer Institute, Bethesda, MD, United States
from 2018 Advances in Malignant Lymphoma conference on June 23, 2018 8:00 AM-10:30 AM
How to design a MATCH trial for lymphoma
Anas Younes
Mem. Sloan Kettering Cancer Ctr., New York, NY, United States
from 2018 Advances in Malignant Lymphoma conference on June 23, 2018 8:00 AM-10:30 AM
Practical considerations for using genome sequencing data for patient selection
David W. Scott
BC Cancer, Vancouver, BC, Canada
from 2018 Advances in Malignant Lymphoma conference on June 23, 2018 8:00 AM-10:30 AM
Molecular typing in DLBL: Subset and match?
Peter W M Johnson
Univ. of Southampton, Southampton, United Kingdom
from 2018 Advances in Malignant Lymphoma conference on June 23, 2018 8:00 AM-10:30 AM
Utilizing genomic sequencing from clinical assays in lymphoma management
Connie Batlevi
Mem. Sloan Kettering Cancer Ctr., New York, NY, United States
from 2018 Advances in Malignant Lymphoma conference on June 23, 2018 8:00 AM-10:30 AM
Panel Discussion
Connie Batlevi
Mem. Sloan Kettering Cancer Ctr., New York, NY, United States
Peter W M Johnson
Univ. of Southampton, Southampton, United Kingdom
David W. Scott
BC Cancer Agency, Vancouver, BC, Canada
Louis M Staudt
National Cancer Institute, Bethesda, MD, United States
Anas Younes
Mem. Sloan Kettering Cancer Ctr., New York, NY, United States
from 2018 Advances in Malignant Lymphoma conference on June 23, 2018 8:00 AM-10:30 AM
Drugs in the curative RCHOP combination exhibit low cross-resistance but not pharmacologic synergy
Adam C Palmer
Harvard Medical School, Boston, MA, United States
from 2018 Advances in Malignant Lymphoma conference on June 23, 2018 11:00 AM-11:30 AM
MHC class II expression is associated with a distinct mutational profile and immune cell landscape of the microenvironment in GCB-DLBCL
Daisuke Ennishi
BC Cancer Agency, Vancouver, BC, Canada
from 2018 Advances in Malignant Lymphoma conference on June 23, 2018 11:00 AM-11:30 AM
DNA and histone methylation as therapeutic targets in lymphoma
Ari M Melnick
Weill Cornell Medical College, New York, NY, United States
from 2018 Advances in Malignant Lymphoma conference on June 23, 2018 2:00 PM-4:00 PM
Targeting EZH2 in lymphoma
Vincent Ribrag
Institut Gustave-Roussy, Villejuif, France
from 2018 Advances in Malignant Lymphoma conference on June 23, 2018 2:00 PM-4:00 PM
Germinal center-derived lymphomas: At the intersection of genetics and epigenetics
Laura Pasqualucci
Columbia University Institute for Cancer Genetics, New York, NY, United States
from 2018 Advances in Malignant Lymphoma conference on June 23, 2018 2:00 PM-4:00 PM
BET inhibitors in lymphoma
Francesco Bertoni
Università della Svizzera italiana, Institute of Oncology Research, Bellinzona, Switzerland
from 2018 Advances in Malignant Lymphoma conference on June 23, 2018 2:00 PM-4:00 PM
Circulating tumor DNA to monitor treatment response and detect resistant clones in indolent lymphoproliferative diseases treated with novel therapies
Constantine S. Tam
Peter MacCallum Cancer Center, East Melbourne, Australia
from 2018 Advances in Malignant Lymphoma conference on June 23, 2018 4:30 PM-6:30 PM
Tumor fingerprints in the liquid biopsy: Immunoglobulin gene rearrangement or CAPP-seq?
Wyndham E Wilson
National Cancer Institute, Bethesda, MD, United States
from 2018 Advances in Malignant Lymphoma conference on June 23, 2018 4:30 PM-6:30 PM
Use of circulating tumor DNA to genotype aggressive lymphomas
Davide Rossi
Università degli Studi del Piemonte Orientale, Vercelli, Switzerland
from 2018 Advances in Malignant Lymphoma conference on June 23, 2018 4:30 PM-6:30 PM
Panel Discussion
Lee M Greenberger
The Leukemia & Lymphoma Society, Rye Brook, NY, United States
Davide Rossi
Università degli Studi del Piemonte Orientale, Vercelli, Switzerland
Constantine S. Tam
Peter MacCallum Cancer Center, East Melbourne, Australia
Wyndham E Wilson
National Cancer Institute, Bethesda, MD, United States
from 2018 Advances in Malignant Lymphoma conference on June 23, 2018 4:30 PM-6:30 PM
Using in vivo CRISPR-based screening to identify lymphoma drug targets
Michael T Hemann
David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA, United States
from 2018 Advances in Malignant Lymphoma conference on June 24, 2018 7:15 AM-8:00 AM
What is the current role and impact of CRISPR screening to define therapeutic targets in lymphoma?
Sandeep S Dave
Duke Univ., Chapel Hill, NC, United States
from 2018 Advances in Malignant Lymphoma conference on June 24, 2018 7:15 AM-8:00 AM
<< first | < prev page: of 3 records per page: next > | last >>
pages: 1 2 3 presentations: 1 to 25 of 71